RTX001 is Edinburgh-based Resolution’s lead product and is described as an engineered, autologous regenerative macrophage therapy for patients living with end-stage liver disease. Credit: Shutterstock / Peakstock

Scottish biopharmaceutical company Resolution Therapeutics has received approval from  Spain’s Agency of Medicines and Medical Products (AEMPS) to expand its Phase I/II EMERALD study of RTX001, a regenerative macrophage therapy, into Spain.

RTX001 is Edinburgh-based Resolution’s lead product. It is described as an engineered, autologous regenerative macrophage therapy for patients living with end-stage liver disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The approval of the open-label, first-in-human trial in Spain marks the second country for the early stages of the trial after Resolutionpreviously secured its first clinical trial authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) earlier this year with the first patients recruited in October.

The company’s EMERALD study will seek to investigate the safety and efficacy of RTX001 in patients with end-stage liver disease, with primary endpoints centered on safety and major clinical events, including death. It will also look to evaluate biomarkers, such as the Model for End-Stage Liver Disease (MELD) score, which is used to assess disease severity and prioritise patients for a liver transplant.

Clifford Brass, chief medical officer of Resolution Therapeutics, said: “We are excited to have received approval from the AEMPS to expand our Phase 1/2 EMERALD study for RTX001 into Spain.

“This builds on the existing clinical trial authorisation in the UK, where patient recruitment is underway, and further demonstrates the momentum Resolution looks to carry into 2025, as we deliver on our mission of developing macrophage therapies to transform the outcomes of patients with inflammatory and fibrotic diseases.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The announcement comes after a presentation before the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2024. Held in San Diego in November,research presented by the company found that its therapy system showed superior anti-fibrotic and anti-inflammatory effects of IL-10-MMP9 engineered macrophages over non-engineered macrophages.

Elsewhere in the treatment of liver diseases, Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4mg in treating metabolic dysfunction-associated steatohepatitis (MASH) alongside moderate to advanced liver fibrosis.